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Introduction
Currently, no consensus exists on a model describing 
endogenous glucose production (EGP) as a function of 
glucagon concentrations. Reliable simulations to determine 
the glucagon dose preventing or treating hypoglycemia or to 
tune a dual-hormone artificial pancreas control algorithm need 
a validated glucoregulatory model including the effect of 
glucagon.
This poster presents the results from the leave-one-out cross-
validation of a glucoregulatory model with interacting effects 
of insulin and glucagon [1]. We present model fits to data, and 
simulations with the model showing the glucagon dose-
response relationship at varying insulin levels [2].
Results
Table 1: Result of leave-one-out cross-validation.
We successfully validated a model describing the 
glucose-insulin-glucagon dynamics by leave-one-out 
cross-validation in seven type 1 diabetes patients. We 
used patient specific parameter sets to establish a 
virtual population. Simulations with the virtual patients 
showed that the ambient insulin level affects the 
maximum EGP response to glucagon, but has little 
influence on the dose yielding half maximum response.
Conclusions
Materials and Methods
Patient Accepted Test-visit fits (Training-visits)
1 A (BD), B (AD)
2 C (ABD), D (ABC)
3 A (BCD), B (ACD)
4 B (ACD)
5 A (BC), B (AC), C (AB)
6 A (BD), D (AB)
7 C (ABD), D (ABC)
8 None
1Zealand Pharma A/S, 2Technical University of Denmark, 3Hvidovre Hospital, 4Danish Diabetes Academy, 5University of Copenhagen
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Q1(t) and Q2(t) are the masses of glucose per BW (μmol/kg) in 
the accessible and non-accessible compartments. Glucose 
concentration (mmol/L) in the accessible compartment is Q1/V 
with V fixed at 160 mL/kg. I(t) is the insulin concentration 
(mIU/L) in the accessible compartment. xi(t) are remote effects 
of insulin (mIU/L). F01 is the non-insulin-dependent glucose 
flux. FR is the renal glucose clearance. k12 and ki are transfer 
rate constants. SD, SE, and ST are insulin sensitivities. 
The model is modified so GGG(t) is the insulin and glucagon 
dependent EGP corresponding to glycogenolysis and GGNG is 
the constant EGP contribution from gluconeogenesis [1].
Eight type 1 diabetes patients received a subcutaneous (SC) 
bolus of insulin (NovoRapid®) on four study days to induce 
mild hypoglycemia followed by a SC bolus of saline (A) or 100 
(B), 200 (C) or 300 (D) µg glucagon (GlucaGen®). Samples were 
analyzed for concentrations of glucagon, insulin, and glucose. 
The PD model is mainly inspired by Hovorka et al. [3].
C(t) is the glucagon concentration (pg/mL) in the accessible 
compartment. Ib,y is the fixed basal insulin concentration 
(mIU/L) for subject y, and E0 is the minimum EGP fixed at 8 
μmol/(kg·min). Emax is the maximum EGP at Ib,y. CE50 is the 
glucagon concentration at half maximum EGP.
Figure 1: Data and model fits of patient 7. Insulin PK (top), 
glucagon  PK (middle), glucose PD (bottom) during visits A-D 
(left to right).
Figure 2: Simulation of glucagon dose-response relationship 
at varying insulin levels.
The PD model validation was carried out as a 4-fold leave-one-
out cross-validation leaving all data from one visit out per fold. 
To quantify the simulation accuracy of the model on datasets 
not used for parameter optimization, the bias was calculated 
by the mean prediction error (MPE) and the precision 
calculated by the mean absolute prediction error (MAPE). Test-
visit fits were accepted if MPE < ±15% and MAPE < 20%.
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All non-outlier visits were used to estimate the final model 
parameters for each patient using maximum a posteriori with 
the CTSM-R package in R (http://ctsm.info/). 
The seven virtual patients each underwent an in silico 
euglycemic (5 mmol/L) clamp study where the insulin infusion 
rate (IIR) was constant at 1-5 times the basal IIR. Meanwhile, 
the responses to glucagon boluses ranging 1 µg-10 mg were 
assessed by 60-minutes area under the curve (AUC60min).
